Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 164

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 164
---

private placement transactions, we issued (i) an aggregate of 899 Depositary Shares to certain secured noteholders of Adhera Therapeutics,
Inc., and (y) an aggregate of 9,098 pre-funded warrants to purchase Depositary Shares to certain of the secured noteholders, and (ii)
issued to Melior 1,417 of our Depositary Shares.

On February 26, 2024, in connection
with our Company’s obligations under a license agreement with Melior, we issued 1,417 Depositary Shares to Bukwang.

On April 29, 2024, in connection
with the closing of the Emtora License Agreement, we issued 1,512 Depositary Shares to Emtora.

On May 24, 2024, in connection
with certain warrant inducement agreements, we issued an aggregate of 12,417 Depositary Shares to certain holders of our Series E Warrants
and Series F Warrants, upon the exercise of 6,290 Series E Warrants and 6,127 Series F Warrants, at an exercise price of $375.00 per share.
In addition, we issued to such holders an aggregate of 9,434 Series G Warrants, and 14,780 Series H Warrants. The aggregate gross proceeds
to the Company were approximately $6.05 million, before deducting agent fees and expenses. Additionally, we issued warrants to purchase
644 of our Depositary Shares in connection with the offering to Ladenburg, as agent, and certain designees of Ladenburg.

On July 22, 2024, in a private placement, we issued and sold (x) Series J Warrants exercisable for 21,315 Depositary Shares, and (y) Series K Warrants to purchase an aggregate of 21,315 Depositary Shares. The warrants are immediately exercisable at an exercise price of $250.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The aggregate gross proceeds to the Company were approximately $5.0 million (including shares sold in a concurrent registered direct offering). Additionally, we issued warrants to purchase 851 of our Depositary Shares in connection with the offering to Ladenburg, as the placement agent in the offering, and certain of its designees.

On May 15, 2025, we entered
into letter agreements with certain accredited holders of our outstanding Series E Warrants, Series H Warrants, Series J Warrants,